Bioenvision Inc. announced Monday that its continuing study of an experimental leukemia treatment shows "encouraging" data for some high-risk groups.
The company's analysis 44 patients showed 36 percent of those with a high-risk genetic profile responded to Bioenvision's clofarabine drug. Moreover, 56 percent of patients older than 70 years of age responded to the drug
